| Products/Services Used | Details | Operation |
|---|---|---|
| Gene Synthesis | HEK293T/17 cells and phCMV1-H11 (A/duck/Memphis/546/1974 (H11N9)) were kindly provided by Dr DavideCorti, Institute for Research in Biomedicine, Switzerland. N1/Cal09and N2 (A/Texas/50/2012 (H3N2), H3N2/Tex12) were synthesised (WT sequence) and subcloned into plasmid expression vector pI.18 (Cox et al. 2002) by Genscript (U.S.A). HIV-1 derived packaging plasmid pCMVΔR8.91 (p8.91) was obtained from Dr Yasu Takeushi, University College London, originating from the laboratory of Dr Didier Trono (Naldini et al. 1996; Zufferey et al. 1997). Plasmid pCSGW originated from (Demaison et al. 2002), the GFP gene was replaced by that encoding firefly luciferase, forming the plasmid pCSFLW by Novartis Vaccines, Italy. | Get A Quote |
Influenza pseudotypes represent an alternative to wild type virus for serological assays. To date, pseudotypes (PV) have predominantly been used as surrogates for wild type viruses in microneutralisation assays, where the surface glycoprotein of interest and a reporter gene (such as Luciferase) are used to assess if virus entry into target cells could be inhibited by serum antibodies. The influenza neuraminidase (NA) has the ability to bud and release new virions with or without the contribution of Haemagglutinin (HA). Influenza pseudotypes expressing NA alone, or with HA, were produced to evaluate the antibody response against NA using the enzyme-linked lectin assay (ELLA). The expression of an avian HA with h... More
